Drug intelligence / Profile preview

Aminotrofic

Development stage
Unknown
Lead developer
Errekappa Euroterapici
Modality
Small Molecules
Administration
Oral
01

Overview

Aminotrofic is a nutritional supplement and food for special medical purposes (FSMP) developed by Errekappa Euroterapici. It is formulated with a specific mixture of essential amino acids—including L-leucine, L-lysine, L-isoleucine, L-valine, L-threonine, L-cystine, L-histidine, L-phenylalanine, L-methionine, L-tyrosine, and L-tryptophan—and is enriched with vitamins B1 (thiamine) and B6 (pyridoxine). The product is designed to stimulate the synthesis of muscle, mitochondrial, and plasma proteins, particularly in patients suffering from muscle mass loss (sarcopenia) or protein malnutrition associated with acute and chronic pathologies. It is indicated for use in conditions such as chronic heart failure, COPD, diabetes, renal and hepatic insufficiency, and recovery from trauma or skin lesions, aiming to improve physical performance and muscle strength even in insulin-resistant states.

Brand names
AminotroficAminotrofic HD
02

Targets

mTOR (Mammalian target of rapamycin kinase)

Beyond the preview

Go deeper on Aminotrofic.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aminotrofic.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call